Attached files

file filename
EX-99.1 - THRESHOLD PHARMACEUTICALS INCv211762_ex99-1.htm
 

 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 25, 2011 (February 16, 2011)


THRESHOLD PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)


Delaware
001-32979
94-3409596
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
  Identification No.)


1300 Seaport Boulevard, Suite 500
Redwood City, California 94063
(Address of principal executive offices)(Zip Code)


(650) 474-8200
(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 

 

On February 16, 2011, Threshold Pharmaceuticals, Inc. issued a press release announcing that the Company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 randomized trial of TH-302 in patients with soft tissue sarcoma.  The press release is attached as Exhibit 99.1 to this Form 8-K.
.
 

Item 9.01                      Financial Statements and Exhibits.

         (d)  Exhibits

Exhibit 99.1                                Press release dated February 16, 2011.

 
 
 

 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
THRESHOLD PHARMACEUTICALS, INC.
 
       
       
 
By:
/s/  Joel A. Fernandes                                                                  
    Joel A. Fernandes  
    Senior Director, Finance and Controller  
       
 
Date:  February 25, 2011

 
 

 
Exhibit Index

 Exhibit No.                                   Description                                                        

Exhibit 99.1                                   Press release dated February 16, 2011.